Results of exogenous GDF11 supplementation – the view of Patient Zero

Phil Newman

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Steve Perry

CEO, GDF11Rejuvenation.com

Results of exogenous GDF11 supplementation in over 100 human volunteers – the view of Patient Zero

Longevity.Technology: One of the most popular speaker sessions at Longevity 2020 was from Steve Perry who shared his experience as the first of 200+ patients who have experimented with GDF11.

GDF11 has recently emerged as a promising anti-aging agent. The naturally occurring molecule GDF11 is crucial for stem cell DNA repair. During aging, stem cells accumulate DNA damage, leading to stem cell senescence, the main characteristics of which is the decline in stem cell quantity and function. Exogenous GDF11 can boost the regenerative potential of the body, and thereby reverse aging and improve the symptoms of age-related conditions.

Was Dexter the dog a cancer survivor? You can find out in this short and compelling video from Steve:

Phil Newman

Editor-in-Chief

Phil is Editor-in-Chief Longevity.Technology and founder of First Longevity which brings together international investors and Longevity start-ups.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The exit math forcing an M&A decade

Results of exogenous GDF11 supplementation – the view of Patient Zero

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Steve Perry

CEO, GDF11Rejuvenation.com

Results of exogenous GDF11 supplementation in over 100 human volunteers – the view of Patient Zero

You might also like

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Junevity takes gene-network reset into skincare

Longevity biotech’s $173 billion in waiting

The $230 billion nobody needs to approve

Perplexity enters the consumer health AI arena

Startup targets ‘untreatable blindness’ with bionic eye system

Science Corp lands $230m to commercialize vision restoration chip

Ergothioneine: The little-known molecule transforming brain health and longevity

COGNITION: FLT’s new brain-boosting supplement that’s redefining mental performance

7 Best l-glutamine supplements to buy in 2024

Reflections from ARDD 2026

Longevity awards reflect a widening field

Japan’s parsley-powered bet on aging among XPRIZE finalists

Results of exogenous GDF11 supplementation – the view of Patient Zero

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Steve Perry

CEO, GDF11Rejuvenation.com

Results of exogenous GDF11 supplementation in over 100 human volunteers – the view of Patient Zero

You might also like

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE